PMID- 7586112
OWN - NLM
STAT- MEDLINE
DCOM- 19951204
LR  - 20181113
IS  - 0832-610X (Print)
IS  - 0832-610X (Linking)
VI  - 42
IP  - 8
DP  - 1995 Aug
TI  - High-dose vecuronium neuromuscular block: a comparison of arrhythmias and onset 
      of block during sufentanil anaesthesia.
PG  - 716-23
AB  - This study compared the heamodynamic effects of sufentanil with those observed 
      following concomitant sufentanil and high-dose vecuronium administration to 
      determine whether vecuronium induces bradyarrhythmias. Sixty coronary artery 
      bypass patients were stratified into beta blocker (n = 30) or non-beta blocker (n 
      = 30) groups and following induction with sufentanil (9 +/- 3 micrograms.kg-1) 
      and midazolam (0.07 +/- 0.04 mg.kg-1), received either succinylcholine 1 mg.kg-1 
      (SxCh), vecuronium 0.3 mg.kg-1 (Vec 0.3), or vecuronium 0.5 mg.kg-1 (Vec 0.5). 
      Using a Holter ECG monitor, bradyarrhythmias were classified as mild (HR 46-50), 
      moderate (HR 40-45) or severe (HR < 40). In the pre-induction period, there were 
      no differences in the incidence of mild, moderate or severe bradyarrhythmias 
      among the SxCh, Vec 0.3 or Vec 0.5 groups, in either the beta blocker or non-beta 
      blocker groups. Following induction, there were similar reductions in mean heart 
      rate and mean arterial pressure in all three muscle relaxant groups in both the 
      beta and the non-beta blocker groups; however, there was no difference in the 
      incidence of mild, moderate or severe bradyarrhythmias among the SxCh, Vec 0.3 or 
      Vec 0.5 groups. The Vec 0.5 beta blocker group had a higher incidence of mild 
      bradyarrhythmias (32 +/- 36%) than the Vec 0.5 non-beta blocker group (2 +/- 3%, 
      P = 0.017). Using EMG recording, the onset time of maximal neuromuscular block 
      for the Vec 0.3 group (108 +/- 17 sec) was longer (P < 0.05) than the SxCh (76 
      +/- 21 sec) and Vec 0.5 (82 +/- 13 sec) groups, which were similar.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Sharpe, M D
AU  - Sharpe MD
AD  - Department of Anaesthesia, University Hospital, University of Western Ontario, 
      London, Canada.
FAU - Murkin, J M
AU  - Murkin JM
FAU - Vannelli, T
AU  - Vannelli T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Can J Anaesth
JT  - Canadian journal of anaesthesia = Journal canadien d'anesthesie
JID - 8701709
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anesthetics, Intravenous)
RN  - 0 (Neuromuscular Nondepolarizing Agents)
RN  - 7E4PHP5N1D (Vecuronium Bromide)
RN  - AFE2YW0IIZ (Sufentanil)
RN  - J2R869A8YF (Succinylcholine)
RN  - R60L0SM5BC (Midazolam)
SB  - IM
MH  - Adrenergic beta-Antagonists/adverse effects/therapeutic use
MH  - Aged
MH  - *Anesthesia, Intravenous
MH  - Anesthetics, Intravenous/*administration & dosage/adverse effects
MH  - Blood Pressure/drug effects
MH  - Bradycardia/*chemically induced
MH  - Cardiac Output/drug effects
MH  - Coronary Artery Bypass
MH  - Drug Interactions
MH  - Electrocardiography, Ambulatory
MH  - Electromyography
MH  - Female
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
MH  - Midazolam/administration & dosage
MH  - Middle Aged
MH  - Neuromuscular Nondepolarizing Agents/*administration & dosage/adverse effects
MH  - Succinylcholine/administration & dosage
MH  - Sufentanil/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Vecuronium Bromide/*administration & dosage/adverse effects
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1007/BF03012671 [doi]
PST - ppublish
SO  - Can J Anaesth. 1995 Aug;42(8):716-23. doi: 10.1007/BF03012671.